Sernova Biotherapeutics Inc (TSX:SVA)
Canada · Delayed Price · Currency is CAD | Market Cap | 45.32M -23.5% |
| Revenue (ttm) | n/a |
| Net Income | -10.29M |
| EPS | -0.03 |
| Shares Out | 377.64M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,555 |
| Open | 0.1100 |
| Previous Close | 0.1100 |
| Day's Range | 0.1100 - 0.1200 |
| 52-Week Range | 0.0850 - 0.2000 |
| Beta | 0.67 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Dec 18, 2026 |
About Sernova Biotherapeutics
Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate natural body functions. Its Cell Pouch creates vascularized organs for the longevity and functionality of therapeutic cells and ensures containment for retrievability. Sernova Biotherapeutics Inc was formerly known as Sernova Corp. and changed its name to Sernova Biotherapeutics Inc in February 2025. Sernova Biotherapeutics Inc ... [Read more]
Financial Performance
Financial StatementsNews
Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial
TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. (“Seraxis”) today announced...
Sernova Biotherapeutics Transcript: Noble Capital Markets Virtual Equity Investor Conference
A merger will create BetaNova Biotherapeutics, integrating advanced cell therapies and a proven delivery device to pursue a functional cure for type 1 diabetes. Clinical trials begin soon, with early efficacy data expected in 2027 and plans for broader patient impact.
Sernova Biotherapeutics to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference
Jonathan Rigby and Will Rust, Ph.D., to Discuss Proposed Merger to Form BetaNova Biotherapeutics and Advance a Differentiated Type 1 Diabetes Cell-Replacement Platform Jonathan Rigby and Will Rust, Ph...
Sernova Biotherapeutics Slides: Corporate presentation
Sernova Biotherapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 24, 2026.
Sernova Biotherapeutics Transcript: M&A announcement
BetaNova Biotherapeutics is formed from a merger, combining proprietary cell therapy, gene-editing, and implantable device technologies to target a functional cure for type 1 diabetes. The merger is structured as an equal partnership, with secured financing to reach key clinical and regulatory milestones, and plans for a NASDAQ listing in early next year.
Sernova Biotherapeutics Press release: M&A announcement
Sernova Biotherapeutics issued a press release on September 11, 2026, disclosing material business information to investors.
Sernova Biotherapeutics Report: Q3 2026
Sernova Biotherapeutics published a report on September 10, 2026 containing material business information for investors and shareholders.
Sernova Biotherapeutics MD&A: Q3 2026
Sernova Biotherapeutics filed a regulatory document on September 10, 2026 disclosing important business information.
Sernova price target lowered to C$1 from C$6 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Sernova (SEOVF) to C$1 from C$6 and keeps a Buy rating on the shares after the company announced an…
Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy
TORONTO and BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. (“Sernova” or the “Company”) (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO), a leading regenerative medicine company focus...
Sernova Biotherapeutics Report: Q2 2026
Sernova Biotherapeutics published a report on June 11, 2026 containing material business information for investors and shareholders.
Sernova Biotherapeutics MD&A: Q2 2026
Sernova Biotherapeutics filed a regulatory document on June 11, 2026 disclosing important business information.
Sernova Biotherapeutics Announces Closing of Recently Approved Financings
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - April 23, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) (XETRA: PSHO) ("Sernova" or the "Company"), a leading regene...
Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - April 9, 2026) - Sernova Biotherapeutics Inc. (TSX: SVA) (OTC: SEOVF) (FSE: PSH0) ("Sernova" or the "Company"), a leading regenerative med...
Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - March 24, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC Pink: SEOVF) (FSE: PSH0) ("Sernova" or the "Company"), a leading regenerative me...
Sernova Biotherapeutics MD&A: Q1 2026
Sernova Biotherapeutics filed a regulatory document on March 13, 2026 disclosing important business information.
Sernova Biotherapeutics Report: Q1 2026
Sernova Biotherapeutics published a report on March 13, 2026 containing material business information for investors and shareholders.
Sernova Biotherapeutics Strengthens Balance Sheet with $7.1 Million in Financings Plus Net Retirement of a Cumulative $17 Million of Debt Subject to Shareholder Approval
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - March 4, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) ("Sernova" or the "Company"), a leading regenerative medicine...
Sernova Biotherapeutics Announces Warrant Amendments
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - February 20, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSH0) ("the Company"), a leading regenerative medicine company ...
Sernova Biotherapeutics Report: Q4 2025
Sernova Biotherapeutics published a report on December 19, 2025 containing material business information for investors and shareholders.
Sernova Biotherapeutics MD&A: Q4 2025
Sernova Biotherapeutics filed a regulatory document on December 19, 2025 disclosing important business information.
Sernova Biotherapeutics Annual report: Q4 2025
Sernova Biotherapeutics has published its Q4 2025 annual report on December 19, 2025.
Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang
Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - October 1, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH0) ("Sernova") a leading regenerative medicine company focus...
Sernova Biotherapeutics Appoints John L. Brooks III, Former Chair and CEO of Joslin Diabetes Research Center, as Chair of the Board of Directors
TORONTO and BOSTON - September 22, 2025 - The Newswire — Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) a leading regenerative medicine company focused on developing it...
Sernova Biotherapeutics MD&A: Q3 2025
Sernova Biotherapeutics filed a regulatory document on September 14, 2025 disclosing important business information.